Managementul aplicării eritropoetinei umane (Eprex) la pacienţii dializaţi

Abstract

Summary. A frequent and hazardous complication of endstage renal diseases ESRD is anemia. In our study we administered recombinant human erythropoietin (Eprex), Epoetin-, Janssen Cilag, to 65 anemic patients with ESRD, who were undergoing hemodialysis. Eprex was given subcutaneously three times weekly after dialysis, and Ht, Er, Hb; predialysis levels of creatinine and blood urea nitrogen, blood protein level, ferrokinetics, and blood pressure were monitored. Our results demonstrate that Eprex is effective, can restore the Ht to normal in many patients with the need for transfusions with their risks of immunologic sensitization and infection. The treatment with Eprex permit to include and maintain the patients in the waiting list for transplantation in a good condition